IART — Q3 2026 Financial Report Analysis

Neurosurgery carried the quarter; a flood, a soft tissue business and one-off gains shaped the rest

Integra LifeSciences, which makes neurosurgery devices (brain shunts, dural grafts and sealants, ultrasonic tissue removal) and tissue-repair products for wounds and reconstructive surgery, grew third-quarter 2026 revenue 2.3% to $411.2 million. It returned to a GAAP profit of $14.9 million, or $0.19 per diluted share, against a $5.4 million loss ($0.07 per share) a year earlier. Growth came from the Neuro franchise, up 6.5% organically, and was held back by a July 17 flash flood at the company's Cincinnati plant, which cost about $7 million of sales, and by a 2.2% decline in the Tissue Reconstruction segment. The bottom line looks better than the operations behind it: nearly all of the quarter's pre-tax profit came from other income (insurance and litigation gains and currency-swap income), not from selling products. On October 2, ahead of the full results, management cut its full-year outlook.

Key metrics

Gross margin is the share of revenue left after the cost of making the products. Operating margin is the share left after also paying for research, sales and administration, before interest and tax. "Organic" growth strips out currency moves, acquisitions and divestitures.

Where the growth came from

Specialty Surgery (about 70% of revenue) grew 3.9% to $304.1 million. The 10-Q attributes the increase, excluding a $0.8 million currency benefit, "primarily" to Neurosurgery and Surgical Instruments, "offset by decreases in our ENT Solutions business." The earnings release breaks this down further:

• Neuro +6.5% organic, driven by CereLink (intracranial pressure monitoring), Certas Plus (programmable shunt valves for hydrocephalus), Bactiseal antimicrobial catheters, DuraSeal, and a "recovery in cranial perforators." Cranial perforators were one of the product lines the FDA cited in its 2024 inspections and that Integra placed on shipping hold, so their return is a sign the quality remediation is reaching customers.
• Instruments -0.9% organic, put down to order timing.
• ENT -1.1%, mainly from a low-single-digit decline in sinus balloons.

The flood hit this segment: the Cincinnati facility "manufactures and supports several products within our Specialty Surgery portfolio," and its disruption "reduced revenues by approximately $7 million." Without that, Specialty Surgery would have grown about 6%.

Tissue Reconstruction (about 30%) fell 2.2% to $107.1 million, "attributable to lower sales of MicroMatrix and Integra Skin, partially offset by growth in PriMatrix and DuraSorb." The 10-Q says the Integra Skin decline was "primarily due to the clearance of backorders in the prior-year period": Q3 2025 was inflated by catch-up shipments, so part of this decline is a tough comparison rather than lost demand. PriMatrix returning to growth matters because it was one of the products recalled from the Boston plant in 2023 and has since been relaunched through a third-party manufacturer. The private-label business, renamed Corporate Partnerships this quarter, was roughly flat.

By region, Asia Pacific was the fastest grower (+12.3% to $47.9 million). The US, at 73% of sales, grew 1.2% to $299.3 million. Europe slipped 1.4%.

Segment profit (on the 2026 cost allocation, with 2025 recast to match): Specialty Surgery earned $90.8 million (29.8% of its sales) vs. $88.8 million (30.3%); Tissue Reconstruction earned $15.5 million (14.5%) vs. $11.4 million (10.4%). Tissue's profit improved even as its sales fell, consistent with lower Braintree transition and remediation costs. Unallocated corporate costs were $87.4 million.

The quality remediation: costs are falling, the fix isn't finished

Integra has spent years working through FDA quality problems. It has open warning letters (formal FDA notices that a facility's quality systems fall short) from 2019 and 2023 at its former Boston tissue plant and from December 2024 at three Massachusetts and New Jersey sites. The 2024 letter covered cranial perforators, cottonoid patties and strips, and collagen-based products. The 10-Q states that until the violations are fixed, the FDA will not approve premarket approval applications (PMAs, the FDA's approval route for the highest-risk Class III devices) for devices reasonably related to them. The company is pursuing PMAs for SurgiMend and DuraSorb in breast reconstruction, targeting "potential FDA approval for SurgiMend in 2027" and DuraSorb "later in 2027."

Remediation costs are coming down. Braintree transition charges (idle capacity, site transfer, quality remediation and impairments tied to replacing the Boston plant) were $8.8 million vs. $14.0 million a year ago. EU medical device regulation compliance costs were $2.6 million vs. $10.6 million. The new Braintree, Massachusetts tissue plant "became operational in June 2026 and is currently ramping up production to support the planned SurgiMend relaunch in the fourth quarter of 2026."

The filing describes no new FDA warning letter or recall this quarter. It does repeat that the FDA "may initiate additional regulatory action without further notice" until the cited issues are resolved.

The Cincinnati flood

The July 17 flood damaged the Cincinnati facility, equipment and inventory. Integra spent about $22.2 million in the quarter on restoration, "primarily due to the write off of unsalvageable inventory and fixed assets" and outside clean-up contractors. Against that it received a $10.0 million insurance payment (net of deductible), booked an $11.4 million receivable for approved claims, and recorded a $4.9 million gain in other income for damaged fixed assets whose insured value exceeded their book value. The net flood item in special charges was only $0.8 million.

What isn't covered yet: the ~$7 million of lost revenue. The 10-Q says "we have not recognized any recoveries for lost revenues"; any business-interruption payment would show up later as other income. Management expects the plant to return to full capacity during the second quarter of 2027, so the revenue drag continues for at least two more quarters.

What the headline numbers hide

• The profit came from below the operating line. Operating income of $18.9 million plus $5.0 million of interest income, minus $23.0 million of interest expense, leaves about $0.9 million. The $15.7 million pre-tax profit therefore rests on $14.7 million of other income (vs. an $0.8 million expense a year ago). The 10-Q lists three sources: higher income on cross-currency swaps ($3.7 million in the quarter), the $4.9 million insurance gain, and a gain from Integra's win in the Fortis arbitration, a dispute with the former owners of ACell over an acquisition earnout that the tribunal decided in Integra's favor in April. None of these is a recurring product profit.
• A low tax rate helped too. The effective tax rate was 5.2% vs. 20.8%, which the 10-Q attributes to "the jurisdictional mix of income." At last year's rate, net income would have been about $12.4 million instead of $14.9 million.
• Adjusted EPS of $0.59 vs. GAAP $0.19. The $31.6 million after-tax gap is $26.9 million of intangible amortization (the non-cash write-down of the cost of acquired technologies and brands) plus $14.8 million of special charges, less a $10.1 million tax effect. The special charges were: Braintree $8.8 million, structural optimization $5.7 million, EU MDR $2.6 million, the flood $0.8 million, and a $3.0 million credit from acquisition-related items, which includes the Fortis gain. Special charges halved from $29.0 million a year ago, which explains much of the GAAP improvement.
• Underlying gross margin fell. GAAP gross margin dipped 0.5 points to 51.0%. The company's adjusted gross margin, a non-GAAP measure that excludes special charges and amortization, fell further: 61.1% vs. 62.9%. The 10-Q does not explain the quarterly decline. The nine-month margin improvement (52.9% vs. 50.9%) is credited to higher revenue and lower Braintree remediation costs. In Q1, Integra booked a $19.0 million receivable for refundable tariffs paid under the IEEPA program the Supreme Court struck down, $3.4 million of which reversed 2025 costs. Since July, Section 301 tariffs of 10.0% to 12.5% apply to certain imports. Tariff costs are a likely factor in the margin, but the filing does not quantify them for the quarter.
• Cash conversion was strong and looks real. Operating cash flow of $96.0 million was about 6.4 times net income. Receivables fell to $249.0 million from $278.8 million at year-end and inventory to $464.5 million from $492.7 million (partly flood write-offs), so cash wasn't flattered by unusual working-capital moves. Year to date, operating cash flow is $128.6 million vs. $38.6 million; the 10-Q credits "the reduced impact of quality and operational issues" and "lower spending on EU MDR compliance and Braintree transition." $16.2 million of tariff refunds received this year also helped.
• No buyback help. Diluted shares rose to 78.6 million from 76.9 million (on the adjusted share count), so per-share results were diluted slightly rather than boosted.
• Guidance was cut before the quarter was reported. On October 2, Integra lowered full-year 2026 revenue guidance from $1.654–$1.695 billion to $1.634–$1.654 billion and adjusted EPS from $2.40–$2.50 to $2.30–$2.40. It cited the flood and "updated assumptions for the broader business"; the October 21 release names "more measured expectations for portions of our Tissue Reconstruction business."

Takeaway: Integra's operations are improving: Neuro is growing 6.5%, remediation costs are falling, and operating cash flow more than doubled. But the operating profit still barely covers the interest bill, and refinancing will raise that bill. GAAP profit this quarter depended on one-time insurance and litigation gains, so the case for the stock rests on cash generation paying down $1.8 billion of debt faster than flood losses and tissue weakness eat into earnings.

Debt and the refinancing

Total borrowings were about $1.83 billion at quarter-end ($1.745 billion under the senior credit facility plus $81.2 million under a receivables securitization facility). Net debt was $1.5 billion, and the company's leverage ratio (debt relative to adjusted earnings before interest, tax, depreciation and amortization) was 3.8x. On October 19 Integra completed a $2.1 billion refinancing: a $600 million Term Loan A, a $600 million revolver, a $450 million Term Loan B and $450 million of 9.5% senior secured notes due 2033. Maturities are now longer, and lenders loosened the leverage covenant so it steps down to 4.25x during 2027 instead of 4.0x. The cost: management expects its effective interest rate to rise "near the high end of the previously communicated 100- to 200-basis-point range" (1 to 2 percentage points). On roughly $1.8 billion of debt, that is about $18–36 million a year. Q3 interest expense was already $23.0 million against $18.9 million of operating income.

Integra also bought the manufacturing assets of Greer Manufacturing, an existing precision-machining supplier, for $15.0 million in cash on October 5. Results will be reported in Neurosurgery.

Outlook

Management guides Q4 2026 revenue to $413–$433 million, a 0.5% to 5.2% decline from a year ago (organic -0.4% to -5.1%), with adjusted EPS of $0.61–$0.71. For the full year it expects $1.634–$1.654 billion in revenue (organic growth of -0.3% to +0.9%), adjusted EPS of $2.30–$2.40 and operating cash flow of about $190–$200 million. With $128.6 million generated through September, that implies roughly $61–71 million in Q4. The adjusted EPS guide includes expected business-interruption insurance recoveries for lost Cincinnati revenue, so part of Q4 earnings depends on how much the insurer pays and when.

Our read: Q4 looks like the low point for reported growth, since the guide already implies a year-over-year decline while the flood drag continues. The things to watch over the next two quarters:

1. Cincinnati's ramp toward full capacity by Q2 2027, and whether a business-interruption payment for lost revenue is booked.
2. The SurgiMend relaunch out of Braintree in Q4. It would be the first product from the new plant, and a test of whether the tissue manufacturing problems are behind the company.
3. Tissue Reconstruction stabilizing. Goodwill headroom is thin: the Tissue Reconstruction reporting unit's fair value exceeded its book value by only 11.3% in this year's impairment test, and Neurosurgery's by 15.3%. A further guidance cut there could bring back the risk of a write-down like 2025's $511.4 million charge.
4. Interest expense after the refinancing, against an operating income that was $18.9 million this quarter.